1 Growth Stock to Buy Before the Next Bull Market
While there's no telling precisely when a new bull market is going to roll around, it will because eventually one always does. That means now's the time to identify shares of businesses that are positioned to soar once sentiment improves.
Biotech Catalyst Pharmaceuticals (NASDAQ: CPRX) is one good candidate. Unlike many of its biotech peers, it's already quite profitable. Here's why it's a good move for investors to consider it right now.
Until early 2023, Catalyst had only one medicine on the market, Firdapse, which treats a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome (LEMS). But don't mistake LEMS' rarity for an indicator of Firdapse's ability to be profitable. In 2022, sales of the drug were $214 million, a jump of 52% compared to 2021.
Source Fool.com
